After over 20 years ... a new remedy representing a 'milestone' to relieve pain

More than 20 years ago, the US Food and Drug Administration announced the approval of a new property that has a revolution in its time. The property known as “Ziconotide”, which so far is sold under the Brialt brands, was the first peptide medication that depends on animal poison to treat chronic pain, as the active substance extracted from the remedy from the Pacific Laster that hunts fish. This medicine belongs to a medicinal family known as non -opioid painkillers, and the mechanism of work depends on the target of calcium -ng channels, which play a decisive role in transferring pain signals from sensory neurons to the spinal cord and then to the brain to work to prevent the feeling of pain. That medicine was a thousand times stronger than morphine, which made it an effective option to treat serious chronic pain that resisted other treatments. However, despite its effectiveness, the way to give it was a major challenge, as it must be linked to a pump planted in the patient’s spinal cord, which limited its use. The drug can also cause serious side effects, including psychological nerve disorders, confusion, nausea and dizziness, because it works on calcium channels that control multiple neurological functions. Since 2004, the year in which this medicine was launched, scientists have tried to devise an effective not -optic medicine to eventually succeed in the effort. A few days ago, the food and drug administration agreed to a new pain relief called ‘Suzetrigine’, thus becoming the first pain reliever adopted for more than 20 years with a completely new mechanism. The new “Suzitigin”, developed by the Boston -based Vertex Pharmaceuticals, will be sold under the brands of Journavx. This drug is a promising step towards reducing dependence on opioids, which has contributed to the addiction crisis and deaths caused by excessive doses in the United States and the world. “Suzitijin” works to impede sodium channels in the neurons responsible for a feeling of pain. This drug is characterized by providing a level of relief similar to opioids, but it does not cause addiction, anesthesia or the risk of an overdose. The opioid crisis is a witness to a serious health crisis associated with opioid addiction, as it is estimated that 9.5 million Americans have abused 12 years or more opiums in 2020, while 2.7 million people use only 278,000 people in last year. The opium crisis began in the 1990s with an increase in the prescription of opioid medicine such as oxycodon and hydraque code to treat chronic pain. Over time, excessive provisions and comfortable access to these drugs have led to the spread of addiction, causing a sharp increase in the deaths caused by excessive doses. This crisis was exacerbated by the pandemic of the coruna, as social isolation and increased psychological stress has described to high levels of medical use of medical use, and the use of illegal opioids. The pollution of psychological stimulants in fentanel or heroin has also contributed to increasing deaths caused by excessive doses. Studies have shown that individuals with opioid use disorder are more vulnerable to viral infection in general, and it is more likely to interrupt treatment and increase psychological stress, which exacerbates the addiction problem. At the beginning of the corona pandemic, drug tests showed an increase in the discovery rate of unwanted fentanel by more than 35%, and the heroin by more than 44%and the avions by more than 10%. Since then, several studies have been showing an increase in the deaths associated with the AFina and an increase in visits to emergency divisions. According to CDC and prevention centers, the number of deaths due to excessive opium doses has increased to 81.857 cases in the 12 months ending in February 2022, compared to 72 thousand and 930 cases during the same period of the previous year. In light of the opium crisis that ruins the world, opinion painkillers have become a very important option to manage pain without being risk of addiction. A major challenge This medicine includes a variety of compounds that work with different mechanisms to relieve pain, providing safe and effective alternatives. Among these drugs are not steroidal anti -inflammatory, such as ibuprofen and naproxen, which reduce inflammation and relieve pain. In addition, medicines such as silicoxip are used, which provide pain relief, while reducing the side effects on the stomach compared to traditional anti -inflammatory. Not -Opioid -pain -dill drugs also contain anti -pollutants such as gababinin and brigabaline, which are used to treat chronic nerves. In addition, antidepressants such as doloxin are used to relieve chronic pain, especially in cases of depression -related pain, and topical painkillers such as Lidocaine, which provides a topical pain relief without causing systemic effects. The non -opioid -pink -darting agents are characterized by various benefits that make it an appropriate alternative to Afunism, including a low risk of addiction, as this medicine does not cause addiction compared to aviation, which makes a safe option for long -term use, in addition to reducing side -side -effects, it is serious non -effects for the side effects of Side -on -pute -effects. The non -opinion -pink -dilly drugs also have the variety of options, as the mechanisms of the work of this medication differ, allowing doctors to choose the most suitable treatment for each case, in addition to their lower costs, where not -opiath painkillers are usually cheaper than opioid drugs, which make them access to patients. Despite these benefits, not -opioid pains have some challenges, such as its limited effectiveness in severe pain, which usually requires the use of opiates, and some have a group of side effects, such as stomach bleeding in the case of non -steroidal anti -inflammatory or dizziness in the case of anti -seizures. Therefore, research efforts are currently not developing a new generation -opioid painkillers, which target new mechanisms to relieve pain by exploring medicine that works on sodium or calcium channels in neurons, which can provide effective pain relief without causing addiction. Sodium channels The sodium channels are considered one of the basic components of the nervous system, as it plays an important role in transferring electrical signals between neurons. These channels are proteins present in the membranes of neurons that control the flow of sodium ions inside and outside the cell, allowing the nerve signals to transfer quickly and efficiently, and when it comes to pain, sodium channels play a major role in generating and transferring pain signals from the ends to the central nervous system. If an infection or inflammation occurs, sensory neurons are exposed to chemical or mechanical warnings that open sodium channels. With this conquest, sodium ions can flow in the cell, leading to the removal of polarization and the generation of action. This signal is transferred to the spinal cord by the nerves, then to the brain, where it is declared pain. In cases of chronic or nervous pain, sodium channel can become overwhelming, leading to an abnormal increase in pain signals. In the case of nervous pain, for example, sodium channels can remain open for a longer period or be open regularly, causing persistent pain signals, even in the absence of any actual injury. Due to the central role of sodium channels in the transmission of pain signals, these channels have become an important target for developing new pain relief. Developing vehicles that impede the specific sodium channels responsible for pain, without affecting other channels needed for natural nerve camps, can be created an effective non -popium housing. A milestone is the drug recently obtained by approving US drug and food management “Suzitijin”, an example of how to target specific sodium channels in the body to develop safer and more effective medicine, by sodium channels known as NAV1.8 in the peripheral nervous system, an alternative to the risk of reducing the risk of reducing side effects. NAV1.8 Sodium channels are essential parts of the peripheral nervous system, as they are mainly found in sensory neurons responsible for transferring pain signals. And when the tissues are damaged or inflammation, these channels are activated, increasing the flow of sodium ions to the inside of the neurons. This flow generates electrical signals that are transferred over the nerves to the spinal cord, then to the brain, where it is declared pain. Suzlystigin works by selectively connecting these channels and preventing them from opening, stopping the flow of sodium ions and reducing the generation of pain signals. One of the main advantages of “Suzystigin” is its high selectivity. Unlike opioid pink -dilled drugs, which work on opium receptors in the brain and cause addiction, Suzitigin only works on NAV1.8 channels in the peripheral nervous system. This means that the drug does not affect other sodium channels in the brain or spinal cord, reducing the serious side effects associated with opioids, such as respiratory depression and anesthesia, which significantly reduces the risk of addiction, which makes Suzitigin a safe option for long -term use. Suzitigin has been tested in various clinical trials to treat acute pain after surgery, such as the removal of the bouquet and stomach. The results showed that patients who received the drug have a significant decrease in pain compared to the imaginary agent. Currently, the use of the drug is examined in the treatment of chronic pain, such as the next nervous pain for herpes and diabetic neuropathy. In its statement, the US Food and Medicine Administration confirmed that clinical experiments showed a major effectiveness of the drug to relieve pain after surgery, describing it as a ‘milestone in the field of acute pain management’. The CEO of the company that produces the drug said this approval is a ‘historic moment’ for about 80 million people in the United States, prescribing doctors medicine to treat acute pain annually. However, despite its benefits, Suzlystigin faces some challenges. Perhaps the drug is not effective in treating very severe pain, which sometimes requires the use of opium. Second, more studies are still needed to understand the better of the mechanism of the work of the drug and its long -term effects. The cost of the drug is high (about $ 15.5 per capsule), compared to traditional painkillers, which can limit access to some patients.